AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06298734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: A high-intensity interval training, aerobic exercise program virtually supervised, home-based, and appointment-based program under direct one-on-one supervision by a trained oncology exercise specialist. Sessions will be conducted via the Zoom platform. Participants will be provided with home stationary bike, heart rate monitor, blood pressure monitor. For participants who do not have a smart device, a Wi-Fi enabled tablet will be provided.
Study NCT06298734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Program
Description: A virtual dietary consultation program supervised by trained research staff. Appointments will be conducted via the Zoom platform. Participants will receive an education handout at the baseline visit.
Study NCT06564597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education and counseling are offered one-on-one at the bedside during discharge and are also provided in the second week after discharge in an outpatient clinic setting.
Study NCT05337566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Pill + Cefuroxime
Description: Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
Study NCT05337566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Cefuroxime
Description: Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
Study NCT05704387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: individualized GDFT
Description: In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV
Study NCT05704387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive fluid therapy strategy
Description: from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
Study NCT06464991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equecabtagene Autoleucel Injection
Description: dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
Study NCT06464991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen~* Cycle1-2：D1, D8, D15, D22；~* Cycle3-6：D1, D15；~* above Cycle7：D1
Study NCT06464991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
Study NCT06464991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11； above cycle 9: D1, D8.
Study NCT06464991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23； for PVd: Cycle1-8：D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
Study NCT05121350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.
Study NCT05121350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin can inhibit the synthesis of DNA and RNA.
Study NCT05121350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin can inhibit the synthesis of DNA and RNA.
Study NCT05121350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arotinib hydrochloride capsule placebo
Description: Placebo of Anlotinib hydrochloride capsule
Study NCT04594811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection.
Study NCT05929313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrbusNeich Scoreflex TRIO
Description: To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
Study NCT05929313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OrbusNeich Scoreflex NC
Description: To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
Study NCT05576649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task difficulty adaptation according to Arvaneh et al. (2019)
Description: The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).
Study NCT05576649 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Random task difficulty
Description: The task difficulty in the P300 speller training is chosen randomly.
Study NCT05576649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task difficulty adaptation according to iterative learning controller
Description: The task difficulty in the P300 speller is determined by an iterative learning controller.
Study NCT05972018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)
Study NCT05972018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)
Study NCT05972018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)
Study NCT06309914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will consume one capsule of the Placebo twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
Study NCT06309914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enovita Grape Seed Extract
Description: Subjects will consume one capsule of Enovita twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
Study NCT06309914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mirtoselect Bilberry Extract
Description: Subjects will consume one capsule of Mirtoselect twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
Study NCT06309914 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virtiva Plus Ginko Biloba Extract
Description: Subjects will consume one capsule of Virtiva Plus twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
Study NCT06217796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: MydCombi
Description: A single metered spray administered with the MydCombi dispenser
Study NCT04594811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) injection.
Study NCT04742257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoRegulator® device
Description: Trans-spinal DCS paired with peripheral DCS
Study NCT04742257 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MyoRegulator® device
Description: Trans-spinal DCS paired with peripheral DCS
Study NCT04817956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: drugs used outside indication, based on biomarker
Study NCT05991167 — intervention group
Intervention type: DEVICE
Intervention: EndeavorRx
Description: EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
Study NCT05362851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYC301-1 & YYC301-2 & YYC301-3
Description: YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day
Study NCT05362851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YYC301 placebo & Celecoxib 200mg
Description: comparator medication
Study NCT05525390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Reality-Enhanced Behavioral Activation
Description: Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc.
Study NCT05525390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Behavioral Activation
Description: Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
Study NCT05603637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation using SmartTouch radiofrequency ablation catheter
Description: Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using radiofrequency energy with SmatTouch ablation catheter (Biosense Webster, USA)
Study NCT05603637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation using Farawave pulsed-field ablation catheter
Description: Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using pulsed-field energy with Farawave ablation catheter (Boston Scientific, USA)
Study NCT04928547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test
Description: Different test
Study NCT05337189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine DNA methylation analysis
Description: Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
Study NCT05337189 — intervention group
Intervention type: PROCEDURE
Intervention: medical imaging and/or cystoscopy and/or pathological examination
Description: Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
Study NCT05721651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib+PD-1
Description: This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;
Study NCT04980781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise and dietary therapy (PED-t)
Description: Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.
Study NCT04980781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation program for PED-t in ERC
Description: Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
Study NCT06097169 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
Study NCT06097169 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
Study NCT06483178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attune knee implant
Description: Attune cementless cruciate retaining rotating platform implant (DePuy Synthes) with a standard gap balancing cruciate sacrificing surgical technique
Study NCT06483178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon knee implant
Description: Triathlon cementless condylar stabilised implant (Stryker) with a standard gap balancing cruciate sacrificing surgical technique
Study NCT06134492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)
Study NCT05772429 — intervention group
Intervention type: DRUG
Intervention: Epidiolex
Description: Administered as an oral solution
Study NCT06274320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A: holistic approach
Description: 2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)
Study NCT06274320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B: Tolak® Standard of use
Description: 4-week Tolak® alone treatment (once daily in the evening)
Study NCT05000281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 600 mg Ibuprofen 3 times a day for up to six weeks.
Study NCT05719376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monofer (experimental)
Description: Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day
Study NCT05719376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: control group
Description: Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
Study NCT06558045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg film-coated tablet
Description: One tablet of the test drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
Study NCT06558045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xarelto 20 mg film-coated tablet
Description: One tablet of the reference drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
Study NCT05749107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Identify AF patients at risk of developing moderate/severe STR and those who will benefit from restoring the normal sinus rhythm
Study NCT05749107 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Proteomic analyses
Description: To identify the mechanisms leading to moderate/severe STR during AF.
Study NCT06429488 — intervention group
Intervention type: OTHER
Intervention: no intervention, questionnaires were used
Description: The following psychological assessment tools were used:~Obsessive-Compulsive Inventory-Revised (OCI-R): An 18-item self-report questionnaire measuring symptoms across six subscales: washing, checking, neutralizing, obsessing, ordering, and hoarding. A score of 21 or higher indicates likely OCD.~Depression Anxiety Stress Scales-21 (DASS-21): A set of three self-report scales assessing stress, depression, and anxiety over 21 items. This shortened version is widely used for research and clinical purposes and is easy to administer.~Patient Health Questionnaire-9 (PHQ-9): A nine-item scale for assessing depressive symptoms. Scores are categorized as: 1-4 (no/minimal), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), and 20-27 (severe depression).~Generalized Anxiety Disorder-7 (GAD-7): A seven-item tool measuring anxiety symptoms and the severity of generalized anxiety disorder (GAD).
Study NCT06492889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
Study NCT05505578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GamerFit Condition
Description: Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.
Study NCT05505578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Condition
Description: Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.
Study NCT04857073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Monitoring
Description: Glucose monitoring consists of finger stick fasting and 2 hours post prandial
Study NCT04857073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Monitoring
Description: Glucose monitoring consists of finger stick fasting and 2 hours post prandial
Study NCT06492889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Participants in both groups will receive one tablet of 200 mg mifepristone
Study NCT06100471 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study in different tissues in identifing new genetic markers related to endometriosis disease
Study NCT05615168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acumen IQ guided hemodynamic optimization
Description: Hypotension prediction index (HPI) available with the Edwards Acumen IQ sensor will be used as an early warning system and a diagnostic screen will be used to guide therapeutic interventions.
Study NCT05615168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Flotrac guided hemodynamic optimization
Description: Therapeutic interventions guided by real time monitored hemodynamic parameters as measured by Edwards Flotrac sensor.